S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Sarepta Therapeutics Stock Forecast, Price & News

+1.19 (+1.43 %)
(As of 10/15/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.90 million shs
Average Volume1.37 million shs
Market Capitalization$6.72 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sarepta Therapeutics logo

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$540.10 million
Book Value
$9.65 per share


Net Income
$-554.13 million
Net Margins




Market Cap
$6.72 billion
Next Earnings Date
11/4/2021 (Estimated)


Overall MarketRank

2.31 out of 5 stars

Medical Sector

250th out of 1,361 stocks

Pharmaceutical Preparations Industry

117th out of 668 stocks

Analyst Opinion: 4.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

Is Sarepta Therapeutics a buy right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 9 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sarepta Therapeutics?

Wall Street analysts have given Sarepta Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sarepta Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Sarepta Therapeutics

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its earnings results on Wednesday, August, 4th. The biotechnology company reported ($1.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.29) by $0.27. The biotechnology company earned $164.09 million during the quarter, compared to analysts' expectations of $161.95 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 94.90% and a negative net margin of 105.73%. The firm's quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the company earned ($1.93) earnings per share.
View Sarepta Therapeutics' earnings history

How has Sarepta Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SRPT stock has decreased by 18.1% and is now trading at $84.19.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SRPT?

20 Wall Street analysts have issued 1-year target prices for Sarepta Therapeutics' shares. Their forecasts range from $87.00 to $215.00. On average, they expect Sarepta Therapeutics' stock price to reach $131.88 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:
  • Douglas S. Ingram, President, Chief Executive Officer & Director
  • Ian M. Estepan, Executive VP, Chief Financial & Accounting Officer
  • Louise Rodino-Klapac, Chief Scientific Officer & Executive VP
  • Gilmore O’Neill, Chief Medical Officer & Executive Vice President
  • Dallan Murray, Chief Commercial Officer & Senior Vice President

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and The Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.03%), Focused Wealth Management Inc (0.00%), Financial Management Network Inc. (0.00%), IBM Retirement Fund (0.00%), NEXT Financial Group Inc (0.00%) and Fifth Third Bancorp (0.00%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics

Which institutional investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc, and Focused Wealth Management Inc. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Hans Lennart Rudolf Wigzell, Joseph Bratica, and M Kathleen Behrens.
View insider buying and selling activity for Sarepta Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Financial Management Network Inc., IBM Retirement Fund, and Fifth Third Bancorp.
View insider buying and selling activity for Sarepta Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $84.19.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics has a market capitalization of $6.72 billion and generates $540.10 million in revenue each year. The biotechnology company earns $-554.13 million in net income (profit) each year or ($7.11) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

Sarepta Therapeutics employs 866 workers across the globe.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is www.sareptatherapeutics.com.

Where are Sarepta Therapeutics' headquarters?

Sarepta Therapeutics is headquartered at 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (857) 242-4000 or via email at [email protected].

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.